124 results about "Systemic disease" patented technology

The invention is directed to manufacturing and testing methods of electronic intraoral devices for diagnose, monitor and treat local and systemic diseases and conditions for humans and animals. More specifically, the current invention deals with manufacturing techniques, testing methods and a testing apparatus of mainly three types of intra-oral devices: (a) electro-stimulators for various applications such as treatment of dry mouth by stimulating saliva secretion, apnea, sleeping disorders, eating disorders (obesity, anorexia, etc.) dysphagia and others, (b) drug delivery devices; and (c) bio-sensing and monitoring devices. The common parts or the devices are: (1) art electronic module embedded in the device: (2) or a power source being embedded in the device; (3) the devices (or part of them) being placed in the oral cavity.

An improved method of treating immune cell mediated systemic diseases, particularly T and B cell mediated diseases, is provided by increasing the systemic exposure, or bioavailibility, of a therapeutic protein. Such therapeutic protein is selected from the group consisting of a monoclonal antibody, a soluble receptor and a soluble ligand which binds to an antigen expressed on the surface of an immunce cell.

A method, apparatus, and surgical technique for the modulation of autonomic function, for the purpose of treating any of several conditions and diseases, including obesity, metabolic disorders, endocrine disorders, diabetes, respiratory disease, asthma, inflammatory disease, immunological disease, infection, cancer, cardiac disease, cardiovascular disease, cerebrovascular disease, stroke, vasospasm, vascular disease, psychiatric disease, depression, affective disorders, anxiety disorders, and other conditions. This includes neural and tissue modulators, including implanted devices, used to modulate efferent and afferent autonomic neurons to influence or control autonomic or other neural function, including modulation of sympathetic and parasympathetic nervous system components as well as their combination.

The invention is directed to novel compositions and methods utilizing virion derived protein nanoparticles for delivery of medical imaging agents and therapeutic agents for the diagnosis and treatment of malignant and systemic diseases.

An intra-bronchial device provides a medicant intra-bronchially. The medicant may be used for controlling biological interaction of an intra-bronchial obstruction device with the patient, to treat a disease or condition of the lungs such as pneumonia or lung cancer, or to treat a systemic disease or condition. The medicant is provided by associating a medicant with the intra-bronchial device, either before, at the time of placement, or after placement. The medicant may overlie at least a portion of the intra-bronchial device, be absorbed into at least a portion of the intra-bronchial device, or be carried in a chamber. The intra-bronchial device may further include an absorptive member, and the medicant is absorbed by the absorptive member.

The current invention provides devices, methods and systems involving application of energy and / or a liquefaction promoting medium to a tissue of interest to generate a liquefied sample comprising tissue constituents so as to provide for rapid tissue sampling, tissue decontamination as well as qualitative and / or quantitative detection of analytes that may be part of tissue constituents (e.g., several types of biomolecules, drugs, and microbes). In addition, the current invention provides specific compositions of the said liquefaction promoting medium so as to facilitate liquefaction, preserve liquefied tissue constituents, and enable delivery of molecules into tissues. Determination of tissue composition in the liquefied tissue sample can be used in a variety of applications, including diagnosis or prognosis of local as well as systemic diseases, evaluating bioavailability of therapeutics in different tissues following drug administration, forensic detection of drugs-of-abuse, evaluating changes in the tissue microenvironment following exposure to a harmful agent, and various other applications. The methods, devices and systems are used to deliver one or more drugs through or into the site of the tissue to be liquefied.

A method and apparatus for the concurrent treatment of multiple oral diseases and defects while promoting general oral hygiene utilizing direct current electricity. Electrodes are used to deliver a direct current to the gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, and regenerative benefits. These benefits include killing oral microbes, increasing oral vasodilation, reducing oral biofilm, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, periodontitis, and oral malodor, and other systemic diseases correlated with oral pathogens.

A method and apparatus for the concurrent treatment of multiple oral diseases and defects while promoting general oral hygiene utilizing electricity are provided for non-human animals. Electrodes are used to deliver an electrical current to the gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, and regenerative benefits. These benefits include killing oral microbes, increasing oral vasodilation, reducing oral biofilm, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, periodontitis, and oral malodor, and other systemic diseases correlated with oral pathogens.

A method and dispenser for treating a systemic disease in a patient in need of such treatment is disclosed. The method comprising maintaining the inspiratory flow rate and volume of the patient to a certain value and then administering a medicament aerosol formulation to the patient using a breath activated inhalation device.

This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and leukocyte antigens that are predictive of diabetic retinopathy (DR) and / or other conditions using protein-conjugated microparticles detectable by a non-invasive detection system, for example, a scanning laser opthalmoscope. In other embodiments, the invention relates to targeted delivery of drugs or other substances to specific regions of an intraluminal surface of a blood vessel using drug-containing microparticles coated with one or more ligand binding partners.

The invention relates to a selenium-rich and zinc-rich lepidium meyenii planting method and lepidium meyenii products. When the lepidium meyenii is planted at areas of different altitudes, selenium and zinc base fertilizer is applied or selenium and zinc leaf fertilizer is sprayed during the growing period, the lepidium meyenii rich in organic selenium and organic zinc is planted, and therefore the functions of the lepidium meyenii products are increased, and the cost of lepidium meyenii raw materials is reduced by more than ten times. The selenium-rich and zinc-rich lepidium meyenii and traditional Chinese medicinal materials are prepared respectively into selenium-rich and zinc-rich lepidium meyenii chewable tablets, selenium-rich and zinc-rich lepidium meyenii powder, selenium-rich and zinc-rich lepidium meyenii liquor, selenium-rich and zinc-rich lepidium meyenii oral liquid, selenium-rich and zinc-rich lepidium meyenii solid and liquid beverages, selenium-rich and zinc-rich lepidium meyenii (instant) tea, selenium-rich and zinc-rich lepidium meyenii (instant) coffee and selenium-rich and zinc-rich lepidium meyenii delicious herbal cuisine. The obvious cooperation complementation effect is produced, and the selenium-rich and zinc-rich lepidium meyenii products are wide in sharing crowd and suitable for industrial production. The lepidium meyenii products are used for rehabilitation of the tumor, the leukemia, the hepatopathy, the cardia-cerebrovascular disease, the urinary systemic disease, the diabetes mellitus and the blood pressure diseases. The lepidium meyenii products are health products for healthy people to keep healthy, beautify, lose weight, tonify Yang and nurse the climacteric syndrome.

The present invention is directed to methods for alleviating the symptoms associated with peripheral neuropathy. The neuropathy may be the result of a genetically inherited condition, systemic disease or exposure to a toxic agent. A reduction or elimination of symptoms is obtained by administering the drug selegiline. The invention is also directed to a method for treating patients with cancer by administering a chemotherapeutic agent known to have a toxic affect on peripheral nerves together with selegiline.

A method and apparatus for the concurrent treatment of multiple oral diseases and defects while promoting general oral hygiene utilizing direct current electricity. Electrodes are used to deliver a direct current to the gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, and regenerative benefits. These benefits include killing oral microbes, increasing oral vasodilation, reducing oral biofilm, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, periodontitis, and oral malodor, and other systemic diseases correlated with oral pathogens.

The invention relates to the technical field of medicines and discloses a method for separating and purifying impurities in a sodium tanshinone IIA sulfonate crude drug. Sodium tanshinone IIA sulfonate is widely used for treating cardiovascular and cerebrovascular diseases and other systemic disease at present. 1, 2-dehydrogenation sodium tanshinone IIA sulfonate, sodium tanshinone IIB sulfonate and 1-hydroxy sodium tanshinone IIA sulfonate are three major impurities in the sodium tanshinone IIA sulfonate crude drug. The method for separating and purifying the impurities in the sodium tanshinone IIA sulfonate crude drug is that a high-speed counter-current chromatography method is used for separating and purifying the three major impurities in the sodium tanshinone IIA sulfonate crude drug. The method has the advantages of being simple, fast, high in recovery rate, large in preparation quantity, high in separation efficiency, good in product purity, convenient and suitable for studying comparison products, and defects of cumbersome operations and long separation periods of traditional preparation methods are overcome.

The present invention relates to a transgenic Trichoderma spp. having a recombinant nucleic acid molecule encoding a bioactive molecule. The present invention also relates to methods for controlling plant disease that involve applying a transgenic strain of Trichoderma spp. plants or plants seeds, where the transgenic strain of Trichoderma spp. has a recombinant nucleic acid molecule encoding a bioactive molecule that is capable of controlling plant disease and conferring systemic disease resistance to the plant or a plant grown from the plant seed. The present invention also relates to a method of delivering a bioactive molecule to a plant or plant seed. The method involves providing a transgenic strain of Trichoderma spp. having a recombinant nucleic acid molecule encoding a bioactive molecule and applying the transgenic strain of Trichoderma ssp. the plant's roots or seeds.

The liquid elicitor of chitin and chitosan and micronutrient trace elements of the present invention involves induced systemic resistance (ISR) / innate immunity responses within plants. Dilute solutions are applied to propagules (fractions of microgram per seed and / or plant), which causes natural biotic defense responses by seedlings and / or plants. The application may be as seed coating, irrigation water, and / or foliar spray, wherein propagules bioactivate systemic disease defenses against bacteria, fungi, insects and parasitic nematodes. Benefits include enhanced biocontrol of seed viability, seed germination, seedling vigor, plant growth, flowering and harvest yields for legumes, grains, potatoes, vegetables, fruits, trees, sugar beet, and grass. By nature, this homeopathic invention benefits the entire environment by being natural, biodegradable, and by promoting beneficial soil organisms. This new class of agricultural chemistry will ameliorate adverse effects of toxic pesticides through use of the present invention in integrated pest management (IPM) programs.

The invention provides compositions and methods for treating diseases and conditions, including systemic diseases and conditions, through an intravenous administration of a selective α-2 adrenergic receptor agonists having a binding affinity of 300 fold or greater for α-2 over α-1 adrenergic receptors. The amounts of the selective α-2 adrenergic receptor agonists are substantially lower than the amounts normally used to cause sedation. The compositions preferably include dexmedetomidine.

The invention relates to an electric respirator which can protect a respiratory system by intercepting, filtering, adsorbing and purifying dust and harmful gases and has pressurizing, heating, cooling, perfuming and medicating functions. The electric respirator consists of an outer respirator, seven filtering materials, an electric fan, an inner respirator, a wind baffling plate and a power cord. A basic component formed by combining the electric fan and the inner respirator has capabilities: 1, being combined with cotton gauze or sponge for baffling and filtering granules, fine sands and dust; 2, being combined with an activated carbon bag for filtering and absorbing the harmful gases, viruses, bacteria, microbes and pestilential and fishy odors; 3, being combined with a heat storage bag and a cold storage bag for adjusting the inhalation temperature; 4, being combined with a sachet for distributing beneficial gases; and 5, being combined with a Chinese herbal medicinal bag for treating various respiratory and systemic diseases through breathing administration.

The invention discloses inhalant, a preparation method thereof, and application of the inhalant as an inhalant carrier with pullulan. The particle diameter of drug particles for lung inhalation in the dry-powder inhalant disclosed by the invention is 0.1-50 mu m, preferably 0.3-15 mu m, more preferably 0.5-5 mu m. Generally, the dosage of drugs inhaled for each time is 0.1 mu g to 500 mg. The effective deposition rate of the inhalant in the lung is increased by 16-400%. The inhalant has high bioavailability and can be used for treating local or systemic diseases. The inhalant disclosed by the invention has important value for increasing the pulmonary delivery efficiency of drugs.

The present invention provides methods for treating or preventing periodontal disease in a mammal subject. The inventive methods comprise topically administering to the subject an effective amount of a H2 antagonist encapsulated in liposomes. Preferably, the H2 antagonist, for example, Cimetidine, is encapsulated into paucilamellar liposomes, such as Novasome® microvesicles. The inventive methods may be used to treat and / or prevent gingivitis, periodontitis, aphthous ulcers, or herpetic stomatitis. Alternatively, the inventive methods may be used to treat and / or prevent a systemic disease associated with periodontal disease, such as cardiovascular diseases, pregnancy complications, and diabetes.

Provided herein is a method for detecting the presence of unhealthy cell in a subject using the expression of PDPK FA / GSK-3α in cell and uses thereof. In another aspect, provided herein is a method for predicting if a subject is systemically unhealthy and at risk of developing systemic diseases and syndromes.

The invention provides a method for detecting pathogenic genes of other system diseases causing cardiovascular symptoms, and provides application of a reagent for detecting pathogenic and / or susceptible genes of other systemic diseases causing cardiovascular symptoms in preparing products for diagnosing other systemic diseases causing the cardiovascular symptoms. The reagent can detect at most 263diseases related genes simultaneously, and a reference can be provided for genetic diagnosis and personalized treatment of sick individuals so as to study causes of other systemic diseases causing the cardiovascular symptoms and to assess risk factors for early intervention and early treatment.

The present invention relates to improved compositions and methods for delivering and expressing therapeutic genes in mammals. More particularly, the invention stems from the unexpected discovery that a remarkable, massive and widespread therapeutic gene delivery and expression is obtained in mammals when a therapeutic gene is incorporated in a viral vector and administered both into the CSF and into the blood of the mammal. Such a combined administration leads to a surprising and substantial therapeutic benefit in the mammal as compared to administration in one single site, and further enables the use of reduced doses of the virus. The invention may be used in any mammal, including human subjects, and is particularly suited to treat multi-systemic diseases, such as motor neuron or lysosomal disorders, where widespread expression of a therapeutic gene is desirable.

The invention relates to the technical field of animal models and concretely, relates to a method for building an animal model with PHF 14 gene knockout-based acute kidney injury and renal fibrosis after injury. The invention builds a model of renal fibrosis after kidney injury under the genetic background of PHF 14 gene knockout under adult conditions and provides essential conditions for researching a use of a PHF 14 gene in fibrotic diseases. Compared with the existing PHF 14 knockout model, the PHF 14 gene knockout provided by the invention does not cause embryonic lethal. A test on adult-stage tamoxifen induced knockout of PHF 14 proves that the PHF 14 gene knockout does not cause embryonic lethal. Compared with a group without knockout, the group subjected to knockout has no substantial pathology of lung, liver and kidney. The method prevents systemic disease state-caused interference on following-up acute kidney injury model making and realizes individual research on use of the gene defect in renal fibrosis pathogenesis.

Disclosed are topical oral compositions comprising a safe and effective amount of an antimicrobial agent in admixture with a pharmaceutically acceptable carrier, the compositions being effective in controlling bacterial-mediated diseases and conditions present in the oral cavity and in inhibiting the spread into the bloodstream of pathogenic oral bacteria, associated bacterial toxins and endotoxins, and resultant inflammatory cytokines and mediators. Also disclosed are methods of use of these topical antimicrobial oral compositions to reduce the risk of developing an oral bacteria-induced systemic disease and to promote whole body health in humans and other animals.

An assay and a method for identifying a prebiotic to treat a subject in need thereof to promote intestinal barrier integrity or to blunt an inflammatory response are provided.

The invention discloses application of an endophytic fungi strain R5-6-1 on prevention and treatment of rice bacterial leaf blight, and belongs to the technical field of plant disease control. The endophytic fungi strain R5-6-1 is a Phialophora oryzae fungi strain R5-6-1 with a preservation number of CGMCC No. 2737. The endophytic fungi strain R5-6-1 can be used for inducing a host to generate systemic disease resistance for the first time, and the control effect on the rice bacterial leaf blight reaches 80.75%. The invention also provides a method for preventing and treating the rice bacterial leaf blight, wherein the method comprises the following steps of: co-culturing the endophytic fungi R5-6-1 and the rice to ensure that the endophytic fungi strain R5-6-1 is fixedly cultured on the root of the rice to prevent leaves from being infected by the rice bacterial leaf blight, and the disease index is reduced by 64. The biological control effect of the Phialophora oryzae on the rice bacterial leaf blight has great value in popularization and application in the agricultural field.

The invention relates to the field of medical equipment, and particularly relates to a false teeth cleaning machine and a false teeth cleaning method. The false teeth cleaning machine can utilize an electrolytic plate assembly for electrolysis of water through arrangement of a cleaning machine body, a control assembly, a cleaning assembly and the electrolytic plate assembly, so that false teeth can be cleaned by using electrolytic water, an organic matter can be effectively degraded, and the false teeth are thoroughly cleaned through cleaning and sterilization. Therefore, mouth health of a denture wearer can be effectively ensured and the risk of other systemic diseases is reduced. According to the false tooth cleaning method, the false teeth are cleaned in the electrolysis process. The method is simple and feasible; and compared with ultrasonic cleaning in the prior art, the method provided by the invention is capable of thoroughly cleaning the false teeth and sterilizing the false teeth. Compared with ultrasonic cleaning, the method is free of noise pollution, and further plays a protecting role for the physical health of the denture wearer.

The invention relates to a pharmaceutical composite which inhibits and / or relieves pruritus caused by dermatosis, mucosa disease or systemic disease or lesion, and is made from derivatives, salt or solvate of phenyl butyric acid and short chain fatty acid with effective dose and a carrier which is acceptable pharmaceutically.

A method of treating a systemic disease in a patient in need of such treatment is disclosed. The method comprising maintaining the inspiratory flow rate and volume of the patient to a certain value and then administering a medicament aerosol formulation to such patient.